Paper Details

  1. Home
  2. Paper Details

Efficacy and safety of alirocumab in reducing lipids and cardiovascular events.

Author: , AvernaMaurizio, BergeronJean, ChaudhariUmesh, El ShahawyMahfouz, FarnierMichel, KasteleinJohn J P, KorenMichael J, KrempfMichel, LangsletGisle, LeporNorman E, LorenzatoChristelle, LucGérald, PordyRobert, RaalFrederick J, RobinsonJennifer G, StroesErik S

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Alirocumab significantly reduced low-density lipoprotein (LDL) cholesterol levels in patients with high cardiovascular risk who were receiving statin therapy at the maximum tolerated dose over a period of 78 weeks. There was evidence of a reduction in the rate of cardiovascular events with alirocumab.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Alirocumab, a monoclonal antibody that inhibits proprotein convertase subtilisin-kexin type 9 (PCSK9), has been shown to reduce low-density lipoprotein (LDL) cholesterol levels in patients who are receiving statin therapy. Larger and longer-term studies are needed to establish safety and...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1056/NEJMoa1501031

データ提供：米国国立医学図書館（NLM）

Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events

The desert of cardiovascular disease is vast and unforgiving. This study investigates the efficacy and safety of alirocumab, a monoclonal antibody, in reducing lipids and cardiovascular events in patients at high risk.

The study found that alirocumab, when added to statin therapy at the maximum tolerated dose, significantly reduced LDL cholesterol levels over a period of 78 weeks. Interestingly, the study also found evidence of a reduction in the rate of cardiovascular events with alirocumab.

A New Weapon in the Fight Against Cardiovascular Disease

The study suggests that alirocumab, like a skilled desert scout, can effectively reduce LDL cholesterol levels and potentially lower the risk of cardiovascular events. This finding offers a promising new weapon in the fight against cardiovascular disease.

A More Promising Outlook

The results of this study provide a more promising outlook for patients at high risk for cardiovascular events. Alirocumab, when combined with statin therapy, appears to be a powerful tool for lowering LDL cholesterol levels and potentially reducing the risk of cardiovascular events. This discovery is like finding a hidden oasis that can offer a lifeline in the desert of cardiovascular disease.

Dr. Camel's Conclusion

This study provides a ray of hope in the vast desert of cardiovascular disease. Alirocumab appears to be a valuable tool for reducing lipids and potentially preventing cardiovascular events. This discovery could lead to improved outcomes for patients at high risk, offering a brighter future in the fight against this prevalent disease.

Date :
  1. Date Completed 2015-04-28
  2. Date Revised 2022-04-08
Further Info :

Pubmed ID

25773378

DOI: Digital Object Identifier

10.1056/NEJMoa1501031

Related Literature

Article Analysis
・Effects of alirocumab injection
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.